This document replaces the Operational note published in January 2022.

These updated commissioning recommendations reflect the loss of exclusivity of apixaban, enabling sufficient stock of generic product to be available to the NHS. The recommendations restate the commitment to ensure undiagnosed and untreated atrial fibrillation (AF) are addressed, as a priority for the improvement of national cardiovascular disease (CVD) outcomes.